Cerebral glucose metabolism and regional homogeneity as predictors of amyloid burden changes in preclinical AD
The findings indicate that baseline ReHo and FDG provide complementary insights into amyloid dynamics in the preclinical phase of Alzheimer's disease. Specifically, ReHo shows potential as a predictive biomarker for early changes in soluble Aβ changes, warranting further investigation into its clinical utility alongside FDG-PET.
Authors
- Aldana Lizarraga
- Raffaele Cacciaglia (ORCID: https://orcid.org/0000-0002-9216-949X)
- Jordi Huguet (ORCID: https://orcid.org/0000-0001-8420-4833)
- Gemma Salvadó (ORCID: https://orcid.org/0000-0002-5210-9230)
- Gwendlyn Kollmorgen
- Kaj Blennow
- Michalis Kassinopoulos (ORCID: https://orcid.org/0000-0003-4312-4401)
- Clara Quijano‐Rubio (ORCID: https://orcid.org/0000-0001-9050-3282)
- Alfa Study
- Marta Milà‐Alomà
- Juan Domingo Gispert
- Marc Suárez‐Calvet
- David Vállez‐Garcia
- Henrik Zetterberg
- Mahnaz Shekari
Institutions
- Roche (Switzerland) (CH)
- University of Wisconsin–Madison (US)
- Universitat Pompeu Fabra (ES)
- Lund University (SE)
- Hong Kong Science and Technology Parks Corporation (HK)
- Sahlgrenska University Hospital (SE)
- Roche Pharma AG (Germany) (DE)
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES)
- Pasqual Maragall Foundation (ES)
- Barcelonaβeta Brain Research Center (ES)
- Hospital Del Mar (ES)
- MRC Prion Unit (GB)
- Wisconsin Division of Public Health (US)
- Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (ES)
- Amsterdam University Medical Centers (NL)
- University College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_100911
- Primary Topic
- Functional Brain Connectivity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00